About REST corepressor 2
REST corepressor 2 (RCOR2) is a protein
from Homo sapiens identified by UniProt accession
Q8IZ40, 523 residues long.
MolForge cross-references it against 0 known binders and
32 disease associations.
Target properties
| Protein name | REST corepressor 2 |
| UniProt accession | Q8IZ40 |
| Gene | RCOR2 |
| Organism | Homo sapiens |
| Length | 523 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (32)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- lysosomal storage disease · score 0.35
- bipolar disorder · score 0.09
- schizophrenia · score 0.08
- unipolar depression · score 0.07
- pulse pressure measurement · score 0.06
- hypertriglyceridemia 2 · score 0.06
- obsessive-compulsive disorder · score 0.06
- attention deficit hyperactivity disorder · score 0.06
- autism spectrum disorder · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IZ40-F1 | alphafold | PREDICTED | 67.30 | — |
Amino-acid sequence (523 residues)
MPSVMEKPSA GSGILSRSRA KTVPNGGQPH SEDDSSEEEH SHDSMIRVGT NYQAVIPECK PESPARYSNK ELKGMLVWSP NHCVSDAKLD KYIAMAKEKH GYNIEQALGM LLWHKHDVEK SLADLANFTP FPDEWTVEDK VLFEQAFGFH GKCFQRIQQM LPDKLIPSLV KYYYSWKKTR SRTSVMDRQA RRLGGRKDKE DSDELEEGRG GVSEGEPDPA DPKREPLPSR PLNARPGPGK KEVQVSQYRH HPLRTRRRPP KGMYLSPEGL TAVSGSPDLA NLTLRGLDSQ LISLKRQVQS MKQTNSSLRQ ALEGGIDPLR PPEANTKFNS RWTTDEQLLA VQAIRRYGKD FGAIAEVIGN KTLTQVKTFF VSYRRRFNLE EVLQEWEAEQ DGAPGAPVPM EEARRGAPLP APALEEDDEV QITSVSTSVP RSVPPAPPPP PPPTSLSQPP PLLRPPLPTA PTLLRQPPPL QQGRFLQPRL APNQPPPPLI RPALAAPRHS ARPGPQPPPT LIGTPLEPPA PSL
Explore REST corepressor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets